A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination with Zanubrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tambiciclib (Primary) ; Zanubrutinib (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors GenFleet Therapeutics

Most Recent Events

20 Feb 2025 Positive data (n=9) presented in a Sellas Life Sciences Group Media Release.
17 Dec 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
03 Apr 2024 Planned number of patients changed from 53 to 63.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight